Another example is rVSV-ZEBOV, the vaccine against the Ebola virus, which was assessed for its effectiveness during the West African epidemic. If we hadn’t taken the experimental vaccine into the epidemic – running clinical trials in the middle of the outbreak to test for safety and efficacy – we’d be without a key tool in our fight to contain the disease in the Democratic Republic of the Congo (DRC).
The research paid for itself in West Africa; now it pays dividends every time the vaccine gets used. This, ultimately, is the role of research in an epidemic – to give us better ways of fighting disease in the future.
To fulfil this role, research needs to be responsive. And that means there needs to be access to flexible funding that can be mobilised quickly when outbreaks occur – for several reasons.
Firstly, putting research into the response is often the only chance of giving those already infected the possibility of receiving treatment, because for many epidemic diseases, there’s nothing currently available.
“One thing we all have to remember is an outbreak is basically a bunch of people who are sick with a disease,” says Professor Peter Horby at the Centre for Tropical Medicine and Global Health, University of Oxford. “Patients are at the heart of outbreaks.”
Moving quickly gives us the best chance of helping them. But a rapid response is also important because an epidemic itself is short – at least by research standards.
“Clinical trials usually take years to set up and fund,” says Horby, “whereas many outbreaks last six to eight weeks.” For rare diseases, this means there’s only a fleeting chance to test possible treatments. So research in an epidemic response needs to be atypical, kicking into gear without delay.
A great example of this is currently underway in the DRC. In response to the current Ebola outbreak, now the second most deadly the world has known, health officials are setting up a randomised controlled trial of four therapeutic treatments to find out how effective they are.
Not only has the trial sprung into action much quicker than usual, the officials have also designed it so that three treatments are compared against a fourth, rather than to no treatment, which is the usual method. In the DRC, this fourth treatment – the ‘control’ – will be ZMapp, a monoclonal antibody treatment; if the trial extends to other countries, one of the other three treatments could be the control.
It’s an excellent example of tailoring the traditional research set-up to fit the situation at hand. They’ve made sure that knowledge can be built while everyone in need receives treatment.
The final way we can use research to prepare for epidemics is to study people, to see how human behaviour contributes to the spread of germs.
Dr Juliet Bedford, founder and director of Anthrologica, is studying burial practices in the DRC to look at how to make them medically safe.
“Viral load is known to be highest at point of death,” says Bedford. “There are certain customary practices about burials and funerals in the DRC – washing the body, dressing the body, braiding the hair of the women – where there’s a high degree of physical contact that really elevates the risk of transmission.”
So, Bedford and her team have been negotiating slightly different practices with communities, to make sure future burials and funerals are medically safe but still acceptable to the community. And it’s worked in the DRC.
Now, says Bedford, we need ongoing funding to build up the same strengths and capacities in other high-priority countries.